Literature DB >> 17051953

Association of haemoglobin level with morbidity and mortality of patients with locally advanced oesophageal carcinoma undergoing radiotherapy--a secondary analysis of three consecutive clinical phase III trials.

K L Zhao1, G Liu, G L Jiang, Y Wang, L J Zhong, Y Wang, W Q Yao, X M Guo, G D Wu, L X Zhu, X H Shi.   

Abstract

AIMS: To investigate the strength of association between anaemia and overall survival, locoregional control, and late radiation complications in patients with locally advanced oesophageal carcinoma undergoing radiotherapy with or without chemotherapy and hyperthermia.
MATERIALS AND METHODS: Between March 1996 and December 2002, 303 patients with locally advanced squamous cell carcinoma of oesophagus enrolled in three consecutive prospective phase III trials conducted in our department were included in this study. These patients received one of the following four irradiation schedules: late course accelerated hyperfractionated (LCAF) radiotherapy alone, LCAF combined with concurrent chemotherapy, LCAF combined with hyperthermia, and continuous accelerated hyperfractionated (CAHF) radiotherapy according to each protocol. According to the haemoglobin levels measured before radiotherapy, patients were stratified to normal haemoglobin group (> or = 12.0 g/dl for men, or > or = 11.0 g/dl for women) or anaemic group (< 12.0 g/dl for men, or < 11.0 g/dl for women). Overall survival, locoregional control rate and late irradiation toxicity were estimated by Kaplan-Meier method.
RESULTS: Of 303 eligible patients, 243 patients (80.2%) had normal haemoglobin level and 60 patients (19.8%) were anaemic. The 5-year overall survival was 39% in patients with normal haemoglobin level, whereas, 22%, with anaemia patients (P = 0.001). The 5-year locoregional control rate at 5 years was 68% in patients with normal haemoglobin, versus 62%, with anaemia patients (P = 0.050). The 5-year rate of radiation toxicity of grade 3 or greater was 29% in patients with normal haemoglobin level, but it was 8%, with anaemic patients (P = 0.033). From multivariate analyses, T stage, location of tumour and haemoglobin level were found to be independent predictors for survival. T stage, gender and haemoglobin level were independent predictors for locoregional control. It was also detected that age and haemoglobin level played as independent predictors for development of radiation toxicity.
CONCLUSIONS: For patients with locally advanced oesophageal carcinoma undergone irradiation, anaemia associated a statistically significant reduction in survival and locoregional control rates, but also decreased radiation toxicity rates. Therefore, haemoglobin level should be considered as a stratification variable in prospective clinical trials.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17051953     DOI: 10.1016/j.clon.2006.04.015

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN: 0936-6555            Impact factor:   4.126


  9 in total

1.  Hemoglobin level influences tumor response and survival after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma.

Authors:  Yoichi Hamai; Jun Hihara; Junya Taomoto; Ichiko Yamakita; Yuta Ibuki; Morihito Okada
Journal:  World J Surg       Date:  2014-08       Impact factor: 3.352

2.  A comparative study of the iron status of patients with oesophageal adenocarcinoma to determine suitability for a clinical trial of iron chelation therapy.

Authors:  S J Ford; M R Bedford; W Pang; A Wood; T Iqbal; C Tselepis; O Tucker
Journal:  Ann R Coll Surg Engl       Date:  2014-05       Impact factor: 1.891

3.  Predictive factors for local control of early glottic squamous cell carcinomas after definitive radiotherapy.

Authors:  Mitsuru Okubo; Tomohiro Itonaga; Tatsuhiko Saito; Sachika Shiraishi; Ryuji Mikami; Akira Sakurada; Shinji Sugahara; Jinho Park; Koichi Tokuuye; Kazuhiro Saito
Journal:  Mol Clin Oncol       Date:  2020-03-30

Review 4.  Systematic review and meta-analysis of tumor biomarkers in predicting prognosis in esophageal cancer.

Authors:  Meilan Chen; Jizheng Huang; Zhenli Zhu; Jun Zhang; Ke Li
Journal:  BMC Cancer       Date:  2013-11-11       Impact factor: 4.430

Review 5.  Neoadjuvant chemoradiotherapy for resectable esophageal cancer: an in-depth study of randomized controlled trials and literature review.

Authors:  Xiao-Feng Duan; Peng Tang; Zhen-Tao Yu
Journal:  Cancer Biol Med       Date:  2014-09       Impact factor: 4.248

6.  Esophageal stenosis and the Glasgow Prognostic Score as independent factors of poor prognosis for patients with locally advanced unresectable esophageal cancer treated with chemoradiotherapy (exploratory analysis of JCOG0303).

Authors:  Tatsuya Okuno; Masashi Wakabayashi; Ken Kato; Masayuki Shinoda; Hiroshi Katayama; Hiroyasu Igaki; Yasuhiro Tsubosa; Takashi Kojima; Hiroshi Okabe; Yusuke Kimura; Tatsuyuki Kawano; Shinichi Kosugi; Yasushi Toh; Hoichi Kato; Kenichi Nakamura; Haruhiko Fukuda; Satoshi Ishikura; Nobutoshi Ando; Yuko Kitagawa
Journal:  Int J Clin Oncol       Date:  2017-07-17       Impact factor: 3.402

7.  A retrospective study: the prognostic value of anemia, smoking and drinking in esophageal squamous cell carcinoma with primary radiotherapy.

Authors:  Fang Zhang; Hui Han; Chuansheng Wang; Jianbo Wang; Guangyu Zhang; Fangli Cao; Yufeng Cheng
Journal:  World J Surg Oncol       Date:  2013-10-01       Impact factor: 2.754

8.  A retrospective study: the prevalence and prognostic value of anemia in patients undergoing radiotherapy for esophageal squamous cell carcinoma.

Authors:  Fang Zhang; Fengyu Cheng; Lifang Cao; Shengchuan Wang; Wei Zhou; Wei Ma
Journal:  World J Surg Oncol       Date:  2014-08-01       Impact factor: 2.754

9.  Survival and prognostic factors of patients with esophageal fistula in advanced esophageal squamous cell carcinoma.

Authors:  Xin Guan; Chao Liu; Tianshuo Zhou; Zhigang Ma; Chunhui Zhang; Bojun Wang; Yang Yao; Xiaona Fan; Zhiwei Li; Yanqiao Zhang
Journal:  Biosci Rep       Date:  2020-01-31       Impact factor: 3.840

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.